Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Omixon’s CEO, Tim Hague will be presenting a short session, titled Optimizing NGS to Address the HLA Typing Challenge during the Annual EFI Region 8 EPT Meeting in Bucharest, Romania next week. Date: 5th of December, 2015 Time: 2:00 – 2:15pm …more
New Feature Highlights A new release of Omixon HLA Twin is now available. Major re-design has taken place to provide a simplified workspace while adding several new features and improvements. Top New Features in HLA Twin 1.1.2 Modified Dashboard similar to a …more